The EMPA-Kidney trial, including patients with chronic kidney disease who had an eGFR of at least 20 but less than 45 mL/min/1.73 m2, or who had an eGFR of at least 45 but less than 90 mL/min/1.73 m2 with a urinary albumin-to-creatinine ratio of at least 200 mg/g, showed that empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes [41]. The gene discussed is ALB; the disease is chronic kidney disease.